Octagon Capital Advisors Acquires $22.58 Million Stake in Xenon Pharmaceuticals Ahead of FDA Filing
On May 15, 2026, Octagon Capital Advisors disclosed a new position in Xenon Pharmaceuticals (XENE), acquiring 490,000 shares valued at approximately $22.58 million during the first quarter of 2026. The stake increased to an estimated value of $28.49 million by March 31, reflecting price appreciation.
Tickers: $XENE
Topics: biopharma institutional investing Xenon Pharmaceuticals